Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Prognostic Relevance of Type 4a Myocardial Infarction and Periprocedural Myocardial Injury in Patients With Non-ST-Segment-Elevation Myocardial Infarction.

Circulation·2025
Same author

Off-Label Use of Balloon-Expandable Transcatheter Valves to Treat Pure Aortic Regurgitation.

The American journal of cardiology·2024
Same author

The role of the vascular surgeon in transcatheter aortic valve implantation.

Vascular·2024
Same author

Predictors of bail-out stenting in patients with small vessel disease treated with drug-coated balloon percutaneous coronary intervention.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2023
Same author

Vascular Access in Patients With Peripheral Arterial Disease Undergoing TAVR: The Hostile Registry.

JACC. Cardiovascular interventions·2023
Same author

Coronary ectasia in different scenarios, primarily in myocardial infarction with nonobstructive coronary artery disease.

Journal of cardiovascular medicine (Hagerstown, Md.)·2023

相关实验视频

Updated: Jul 14, 2026

Surgical Swine Model of Chronic Cardiac Ischemia Treated by Off-Pump Coronary Artery Bypass Graft Surgery
09:12

Surgical Swine Model of Chronic Cardiac Ischemia Treated by Off-Pump Coronary Artery Bypass Graft Surgery

Published on: March 27, 2018

手术前的C-反应蛋白和白细胞计数水平预测了冠状动脉血管造形术后9个月的死亡率,用于治疗未受保护的左主冠状动脉狭窄.

Tullio Palmerini1, Antonio Marzocchi, Cinzia Marrozzini

  • 1Istituto di Cardiologia, Policlinico S. Orsola, Università di Bologna, 40 138 Bologna, Italy. tulliopalmerini@hotmail.com

Circulation
|October 6, 2005
PubMed
概括

在未受保护的左主冠状动脉 (ULMCA) 支架之前,C反应蛋白 (CRP) 水平升高预测死亡和心肌梗塞 (MI) 的风险更高. 炎症标志物可能有助于ULMCA干预措施的风险分层.

更多相关视频

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
07:25

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Published on: September 22, 2020

相关实验视频

Last Updated: Jul 14, 2026

Surgical Swine Model of Chronic Cardiac Ischemia Treated by Off-Pump Coronary Artery Bypass Graft Surgery
09:12

Surgical Swine Model of Chronic Cardiac Ischemia Treated by Off-Pump Coronary Artery Bypass Graft Surgery

Published on: March 27, 2018

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
07:25

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Published on: September 22, 2020

科学领域:

  • 心脏病学 心脏病学
  • 干预心脏病学 干预心脏病学
  • 生物标志物 生物标志物

背景情况:

  • 缺乏准确的手术前风险分层,对于接受支架的未受保护左主冠状动脉 (ULMCA) 狭窄的患者.
  • 炎症标记物的预测值,如C反应蛋白 (CRP),纤维素和白细胞计数,对于ULMCA支架后的结果需要检查.

研究的目的:

  • 评估手术前C-反应蛋白 (CRP),纤维素和白细胞计数的预测值,用于未受保护左主冠状动脉 (ULMCA) 狭窄支架后的9个月临床结果.

主要方法:

  • 在接受ULMCA支架的83名患者中,前性测量CRP,纤维素和白细胞计数.
  • 使用输出药物的支架 (n=42) 和裸金属支架 (n=41).
  • 评估终点,包括死亡,心肌梗塞 (MI),并在9个月的随访中对目标病变进行再血管化.

主要成果:

  • 与正常水平相比,较高的CRP水平 (>3 mg/L) 与明显更高的死亡率 (19% vs 0%) 和死亡/MI (31% vs 0%) 相关.
  • 多变量分析确定了CRP水平和白细胞数量最高的三分位数作为死亡的独立预测因素.
  • 最高CRP,白细胞计数和急性冠状动脉综合征的三位数独立预测了死亡/MI的结合终点.

结论:

  • 术前CRP水平升高表明ULMCA支架后死亡和死亡/MI风险增加.
  • 炎症风险评估可能有助于选择具有非常低风险的穿皮冠状动脉干预的患者.
  • 白细胞计数也成为ULMCA支架后不良结果的独立预测指标.